SCI Pharmtech revenue rises to NT$149.0M in 2026 vs NT$51.8M
SCI Pharmtech Inc. reports 2026 revenue of NT$148,954,000 versus NT$51,806,000 in 2025, and Jan–Aug revenue of NT$988,413,000 versus NT$865,442,000 in 2025, per Taiwan Stock Exchange.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.